Biotech News
Related news
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
MNKDMannKind2026-10-14 20:01 EST
MannKind to Participate in the Chardan Healthcare Conference
VKTXViking Therapeutics2026-11-03 21:30 EST
Viking Therapeutics to Participate at Upcoming Investor Conferences
MLYSMineralys Therapeutics2026-11-03 21:05 EST
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
NAMSNewAmsterdam Pharma2026-11-03 13:00 EST
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
CVRXCVRx2026-11-02 21:02 EST
CVRx to Participate in Upcoming Investor Conferences
SENSSenseonics2026-10-22 12:00 EST
Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
SENSSenseonics2026-09-10 12:00 EST
Senseonics To Participate in Upcoming Institutional Investor Conferences
NAMSNewAmsterdam Pharma2026-09-02 12:00 EST
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
LXRXLexicon Pharmaceuticals2026-09-01 20:05 EST
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-11-10 13:00 EST
MannKind to Participate in Upcoming Investor Conferences
MNKDMannKind2026-11-05 21:01 EST
MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-10-29 20:01 EST
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
MNKDMannKind2026-10-14 20:01 EST
MannKind to Participate in the Chardan Healthcare Conference
MNKDMannKind2026-10-10 00:00 EST
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
Stock data
- Close
- 3.95 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
